Steve Chapin
About Steve Chapin
Steve Chapin is a Director at Bolt Biotherapeutics, Inc., specializing in monoclonal antibody generation and cancer immunotherapy. He has a diverse background in research and development, with previous roles at various institutions including the University of California, San Francisco and Astellas Pharma.
Current Role at Bolt Biotherapeutics
Steve Chapin has been serving as Director at Bolt Biotherapeutics, Inc. since 2017. In this role, he focuses on advancing the company's initiatives in cancer immunotherapy. His responsibilities include overseeing the development of monoclonal antibodies and ensuring alignment with broader strategic goals in drug discovery and development.
Previous Experience at University of California, San Francisco
Steve Chapin worked at the University of California, San Francisco, where he held two positions. He was a Postdoctoral Fellow from 1993 to 1997 for four years, followed by a role as a Post-Graduate Researcher from 1997 to 1998 for one year. His time at UCSF contributed to his expertise in cancer research and assay design.
Educational Background in Biology and Cell Biology
Steve Chapin earned a Bachelor of Arts in Biology from the University of California, Santa Cruz, from 1980 to 1984. He furthered his education at the University of California, Los Angeles, where he obtained a Ph.D. in Cell Biology from 1985 to 1992. This educational foundation supports his extensive knowledge in scientific research and drug development.
Expertise in Monoclonal Antibody Generation
Steve Chapin specializes in monoclonal antibody generation, utilizing both in-house and outsourced methods. His expertise extends to designing assays and cell lines specifically for cancer immunotherapy, with a focus on early-phase discovery through Investigational New Drug (IND) applications. His technical background also includes receptor trafficking and cytoskeleton studies.
Professional Experience in the Biotech Industry
Throughout his career, Steve Chapin has held various positions in the biotech industry. He was a Senior Scientist at Marin Biologic Laboratories from 2015 to 2017, a Staff Scientist III at Maxygen from 2006 to 2009, and an Associate Director at Astellas Pharma from 2011 to 2013. He also served as Senior Scientist and Head of the Assay/Screening Group at Planet Biotechnology from 2004 to 2006.